title: Opportunities in respiratory drug delivery.
abstract: A wide range of asthma and chronic obstructive pulmonary disease products are soon to be released onto the inhaled therapies market and differentiation between these devices will help them to gain market share over their competitors. Current legislation is directing healthcare towards being more efficient and cost-effective in order to continually provide quality care despite the challenges of aging populations and fewer resources. Devices and drugs that can be differentiated by producing improved patient outcomes would, therefore, be likely to win market share. In this perspective article, the current and potential opportunities for the successful delivery and differentiation of new inhaled drug products are discussed.
authors.affiliation: Respironics Respiratory Drug Delivery (UK) Ltd, a business of Philips Electronics UK Limited, Chichester, West Sussex, UK.
authors.forename: John N
authors.initials: JN
authors.lastname: Pritchard
authors.forename: Rachael D
authors.initials: RD
authors.lastname: Giles
mesh_terms: D000280:Administration, Inhalation; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage* / Q000191:economics; D001249:Asthma / Q000188:drug therapy* / Q000191:economics; D003362:Cost-Benefit Analysis; D016503:Drug Delivery Systems / Q000191:economics / Q000379:methods*; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration*; D057915:Drug Substitution / Q000191:economics / Q000379:methods; D006801:Humans; D055118:Medication Adherence; D009330:Nebulizers and Vaporizers; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000191:economics; D012107:Research Design; D013678:Technology, Pharmaceutical; D017216:Telemedicine / Q000458:organization & administration
chemical_list: D018927:Anti-Asthmatic Agents